Antoine Drieu

Mr. Antoine Drieu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Science
Verified
Journal Article
Closed access
PDF file
ACAndrea Cugurra
Andrea Cugurra
TMTornike Mamuladze
Tornike Mamuladze
JRJustin Rustenhoven
Justin Rustenhoven
TDTaitea Dykstra
Taitea Dykstra
GBGiorgi Beroshvili
Giorgi Beroshvili
JKJonathan Kipnis
Jonathan Kipnis
Getting around the blood–brain barrier: The meninges comprise three membranes that surround and protect the central nervous system (CNS). Recent studies have noted the existence of myeloid cells resident there, but little is known about their ontogeny and function, and whether other meningeal immune cell populations have important roles remains unclear (see the Perspective by Nguyen and Kubes). Cugurra et al. found in mice that a large proportion of continuously replenished myeloid cells in the dura mater are not blood derived, but rather transit from cranial bone marrow through specialized channels. In models of CNS injury and neuroinflammation, the authors demonstrated that these myeloid cells have an immunoregulatory phenotype compared with their more inflammatory blood-derived counterparts. Similarly, Brioschi et al. show that the meninges host B cells that are also derived from skull bone marrow, mature locally, and likely acquire a tolerogenic phenotype. They further found that the brains of aging mice are infiltrated by a second population of age-associated B cells, which come from the periphery and may differentiate into autoantibody-secreting plasma cells after encountering CNS antigens. Together, these two studies may inform future treatment of neurological diseases. Science , abf7844, abf9277, this issue p. eabf7844 , p. eabf9277 ; see also abj8183, p. 396

27 January 2021 in Cell
Verified
Journal Article
Closed access
JRJustin Rustenhoven
Justin Rustenhoven
ADAntoine Drieu
Antoine Drieu
TMTornike Mamuladze
Tornike Mamuladze
KLKalil Alves de Lima
Kalil Alves de Lima
TDTaitea Dykstra
Taitea Dykstra
JKJonathan Kipnis
Jonathan Kipnis

9 November 2022 in Nature
Verified
Journal Article
Open access
PDF file
ADAntoine Drieu
Antoine Drieu
SDSiling Du
Siling Du
SSSteffen Storck
Steffen Storck
JRJustin Rustenhoven
Justin Rustenhoven
ZPZachary Papadopoulos
Zachary Papadopoulos
JKJonathan Kipnis
Jonathan Kipnis
Macrophages are important players in the maintenance of tissue homeostasis1. Perivascular and leptomeningeal macrophages reside near the central nervous system (CNS) parenchyma2, and their role in CNS physiology has not been sufficiently well studied. Given their continuous interaction with the cerebrospinal fluid (CSF) and strategic positioning, we refer to these cells collectively as parenchymal border macrophages (PBMs). Here we demonstrate that PBMs regulate CSF flow dynamics. We identify a subpopulation of PBMs that express high levels of CD163 and LYVE1 (scavenger receptor proteins), closely associated with the brain arterial tree, and show that LYVE1+ PBMs regulate arterial motion that drives CSF flow. Pharmacological or genetic depletion of PBMs led to accumulation of extracellular matrix proteins, obstructing CSF access to perivascular spaces and impairing CNS perfusion and clearance. Ageing-associated alterations in PBMs and impairment of CSF dynamics were restored after intracisternal injection of macrophage colony-stimulating factor. Single-nucleus RNA sequencing data obtained from patients with Alzheimer’s disease (AD) and from non-AD individuals point to changes in phagocytosis, endocytosis and interferon-γ signalling on PBMs, pathways that are corroborated in a mouse model of AD. Collectively, our results identify PBMs as new cellular regulators of CSF flow dynamics, which could be targeted pharmacologically to alleviate brain clearance deficits associated with ageing and AD.

7 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
LSLeon Smyth
Leon Smyth
DXDi Xu
Di Xu
SOSerhat V. Okar
Serhat V. Okar
TDTaitea Dykstra
Taitea Dykstra
JRJustin Rustenhoven
Justin Rustenhoven
JKJonathan Kipnis
Jonathan Kipnis

28 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
LJLi-Feng Jiang-Xie
Li-Feng Jiang-Xie
ADAntoine Drieu
Antoine Drieu
KBKesshni Bhasiin
Kesshni Bhasiin
DQDaniel Quintero
Daniel Quintero
ISIgor Smirnov
Igor Smirnov
JKJonathan Kipnis
Jonathan Kipnis

4 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NDNicolas Dupré
Nicolas Dupré
ADAntoine Drieu
Antoine Drieu
AJAnne Joutel
Anne Joutel
Cerebral small vessel disease (cSVD) encompasses a heterogeneous group of age-related small vessel pathologies that affect multiple regions. Disease manifestations range from lesions incidentally detected on neuroimaging (white matter hyperintensities, small deep infarcts, microbleeds, or enlarged perivascular spaces) to severe disability and cognitive impairment. cSVD accounts for approximately 25% of ischemic strokes and the vast majority of spontaneous intracerebral hemorrhage and is also the most important vascular contributor to dementia. Despite its high prevalence and potentially long therapeutic window, there are still no mechanism-based treatments. Here, we provide an overview of the recent advances in this field. We summarize recent data highlighting the remarkable continuum between monogenic and multifactorial cSVDs involving NOTCH3 , HTRA1 , and COL4A1/A2 genes. Taking a vessel-centric view, we discuss possible cause-and-effect relationships between risk factors, structural and functional vessel changes, and disease manifestations, underscoring some major knowledge gaps. Although endothelial dysfunction is rightly considered a central feature of cSVD, the contributions of smooth muscle cells, pericytes, and other perivascular cells warrant continued investigation.